BioCentury
ARTICLE | Company News

AuricX Pharmaceuticals, SRI International deal

January 19, 2009 8:00 AM UTC

AuricX received exclusive, worldwide rights to develop and commercialize SRI's preclinical oral formulation of vancomycin to treat methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resis...